Effectiveness and safety of different doses of tenecteplase in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis
Tenecteplase is a modified recombinant tissue-plasminogen activator, which is effective and safe in the treatment of acute ischemic stroke. However, the therapeutic dose of tenecteplase has been controversial. The purpose of this study is to systematically investigate the efficacy and safety of diff...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2021-01, Vol.100 (3), p.e23805-e23805 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e23805 |
|---|---|
| container_issue | 3 |
| container_start_page | e23805 |
| container_title | Medicine (Baltimore) |
| container_volume | 100 |
| creator | Chen, Guanfeng Bai, Chunfeng Zhu, Zhou Li, Junheng Shao, Sen |
| description | Tenecteplase is a modified recombinant tissue-plasminogen activator, which is effective and safe in the treatment of acute ischemic stroke. However, the therapeutic dose of tenecteplase has been controversial. The purpose of this study is to systematically investigate the efficacy and safety of different doses of tenecteplase thrombolytic therapy for acute ischemic stroke.
Computer retrieval of English databases (PubMed, EMBASE, Web of Science, the Cochrane Library) and Chinese databases (CNKI, Wanfang, Viper, and Chinese Biomedical Database) is conducted for a randomized controlled clinical study on thrombolytic treatment of acute ischemic stroke with different doses of tenecteplase from the establishment of the database to October 2020. Two researchers independently conduct data extraction and literature quality evaluation on the quality of the included studies, and meta-analysis is conducted on the included literatures using RevMan5.3 software.
In this study, National Institute of Health Stroke Scale (NIHSS) score, Modified Rankin Scale (mRS) score scale, symptomatic intracranial hemorrhage (SICH) incidence, All-cause mortality, and so on are used to evaluate the efficacy and safety of tenecteplase thrombolytic therapy in acute ischemic stroke with different doses.
This study will provide reliable evidence-based evidence for the clinical application of different doses of tenecteplase in thrombolytic therapy for acute ischemic stroke.
DOI 10.17605/OSF.IO/2MPCW. |
| doi_str_mv | 10.1097/MD.0000000000023805 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7837936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2487156812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3554-988ee6e688eb92ac51fbfe0d045e4a048d7dd9659579ad8655f8a4dbc0c535703</originalsourceid><addsrcrecordid>eNpdkctuFDEQRS0EIkPgC5CQl2w6-NndZoEUJeEhJWIDa8tjl-km7vZgu2c0n8Lf4smE8PCmpLqnbrl0EXpJyRklqntzc3lG_jzGeyIfoRWVvG2kasVjtKpd2XSqEyfoWc7fCaG8Y-IpOuFcCqmEWKGfV96DLeMWZsgZm9nhbDyUPY4eu7GKCeaCXcyQD61SOVtgE0wGPM64DIBLAlOmA1YBY5dSlWwHmEaLc0nxFt7ic7xJsUQbA_Yx4bzPBSZTKpFgO8LubvMExTRmNmGfx_wcPfEmZHhxX0_R1_dXXy4-NtefP3y6OL9uLJdSNKrvAVpoa1krZqykfu2BOCIkCENE7zrnVCuV7JRxfSul741wa0us5LIj_BS9O_pulvUEztY7kgl6k8bJpL2OZtT_KvM46G9xq7ued4q31eD1vUGKPxbIRU_1fAjBzBCXrJnoOyrbnrKK8iNqU8w5gX9YQ4k-hKpvLvX_odapV3__8GHmd4oVEEdgF0OBlG_DsoOkBzChDHd-9XjWMMIooYyR5mAt-C8KzbD_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487156812</pqid></control><display><type>article</type><title>Effectiveness and safety of different doses of tenecteplase in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Guanfeng ; Bai, Chunfeng ; Zhu, Zhou ; Li, Junheng ; Shao, Sen</creator><creatorcontrib>Chen, Guanfeng ; Bai, Chunfeng ; Zhu, Zhou ; Li, Junheng ; Shao, Sen</creatorcontrib><description>Tenecteplase is a modified recombinant tissue-plasminogen activator, which is effective and safe in the treatment of acute ischemic stroke. However, the therapeutic dose of tenecteplase has been controversial. The purpose of this study is to systematically investigate the efficacy and safety of different doses of tenecteplase thrombolytic therapy for acute ischemic stroke.
Computer retrieval of English databases (PubMed, EMBASE, Web of Science, the Cochrane Library) and Chinese databases (CNKI, Wanfang, Viper, and Chinese Biomedical Database) is conducted for a randomized controlled clinical study on thrombolytic treatment of acute ischemic stroke with different doses of tenecteplase from the establishment of the database to October 2020. Two researchers independently conduct data extraction and literature quality evaluation on the quality of the included studies, and meta-analysis is conducted on the included literatures using RevMan5.3 software.
In this study, National Institute of Health Stroke Scale (NIHSS) score, Modified Rankin Scale (mRS) score scale, symptomatic intracranial hemorrhage (SICH) incidence, All-cause mortality, and so on are used to evaluate the efficacy and safety of tenecteplase thrombolytic therapy in acute ischemic stroke with different doses.
This study will provide reliable evidence-based evidence for the clinical application of different doses of tenecteplase in thrombolytic therapy for acute ischemic stroke.
DOI 10.17605/OSF.IO/2MPCW.</description><identifier>ISSN: 0025-7974</identifier><identifier>ISSN: 1536-5964</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000023805</identifier><identifier>PMID: 33545944</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Fibrinolytic Agents - administration & dosage ; Fibrinolytic Agents - therapeutic use ; Humans ; Ischemic Stroke - drug therapy ; Meta-Analysis as Topic ; Randomized Controlled Trials as Topic ; Study Protocol Systematic Review ; Systematic Reviews as Topic ; Tenecteplase - administration & dosage ; Tenecteplase - therapeutic use</subject><ispartof>Medicine (Baltimore), 2021-01, Vol.100 (3), p.e23805-e23805</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3554-988ee6e688eb92ac51fbfe0d045e4a048d7dd9659579ad8655f8a4dbc0c535703</cites><orcidid>0000-0002-3578-5704</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837936/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837936/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33545944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Guanfeng</creatorcontrib><creatorcontrib>Bai, Chunfeng</creatorcontrib><creatorcontrib>Zhu, Zhou</creatorcontrib><creatorcontrib>Li, Junheng</creatorcontrib><creatorcontrib>Shao, Sen</creatorcontrib><title>Effectiveness and safety of different doses of tenecteplase in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Tenecteplase is a modified recombinant tissue-plasminogen activator, which is effective and safe in the treatment of acute ischemic stroke. However, the therapeutic dose of tenecteplase has been controversial. The purpose of this study is to systematically investigate the efficacy and safety of different doses of tenecteplase thrombolytic therapy for acute ischemic stroke.
Computer retrieval of English databases (PubMed, EMBASE, Web of Science, the Cochrane Library) and Chinese databases (CNKI, Wanfang, Viper, and Chinese Biomedical Database) is conducted for a randomized controlled clinical study on thrombolytic treatment of acute ischemic stroke with different doses of tenecteplase from the establishment of the database to October 2020. Two researchers independently conduct data extraction and literature quality evaluation on the quality of the included studies, and meta-analysis is conducted on the included literatures using RevMan5.3 software.
In this study, National Institute of Health Stroke Scale (NIHSS) score, Modified Rankin Scale (mRS) score scale, symptomatic intracranial hemorrhage (SICH) incidence, All-cause mortality, and so on are used to evaluate the efficacy and safety of tenecteplase thrombolytic therapy in acute ischemic stroke with different doses.
This study will provide reliable evidence-based evidence for the clinical application of different doses of tenecteplase in thrombolytic therapy for acute ischemic stroke.
DOI 10.17605/OSF.IO/2MPCW.</description><subject>Fibrinolytic Agents - administration & dosage</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Humans</subject><subject>Ischemic Stroke - drug therapy</subject><subject>Meta-Analysis as Topic</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Study Protocol Systematic Review</subject><subject>Systematic Reviews as Topic</subject><subject>Tenecteplase - administration & dosage</subject><subject>Tenecteplase - therapeutic use</subject><issn>0025-7974</issn><issn>1536-5964</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctuFDEQRS0EIkPgC5CQl2w6-NndZoEUJeEhJWIDa8tjl-km7vZgu2c0n8Lf4smE8PCmpLqnbrl0EXpJyRklqntzc3lG_jzGeyIfoRWVvG2kasVjtKpd2XSqEyfoWc7fCaG8Y-IpOuFcCqmEWKGfV96DLeMWZsgZm9nhbDyUPY4eu7GKCeaCXcyQD61SOVtgE0wGPM64DIBLAlOmA1YBY5dSlWwHmEaLc0nxFt7ic7xJsUQbA_Yx4bzPBSZTKpFgO8LubvMExTRmNmGfx_wcPfEmZHhxX0_R1_dXXy4-NtefP3y6OL9uLJdSNKrvAVpoa1krZqykfu2BOCIkCENE7zrnVCuV7JRxfSul741wa0us5LIj_BS9O_pulvUEztY7kgl6k8bJpL2OZtT_KvM46G9xq7ued4q31eD1vUGKPxbIRU_1fAjBzBCXrJnoOyrbnrKK8iNqU8w5gX9YQ4k-hKpvLvX_odapV3__8GHmd4oVEEdgF0OBlG_DsoOkBzChDHd-9XjWMMIooYyR5mAt-C8KzbD_</recordid><startdate>20210122</startdate><enddate>20210122</enddate><creator>Chen, Guanfeng</creator><creator>Bai, Chunfeng</creator><creator>Zhu, Zhou</creator><creator>Li, Junheng</creator><creator>Shao, Sen</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3578-5704</orcidid></search><sort><creationdate>20210122</creationdate><title>Effectiveness and safety of different doses of tenecteplase in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis</title><author>Chen, Guanfeng ; Bai, Chunfeng ; Zhu, Zhou ; Li, Junheng ; Shao, Sen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3554-988ee6e688eb92ac51fbfe0d045e4a048d7dd9659579ad8655f8a4dbc0c535703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Fibrinolytic Agents - administration & dosage</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Humans</topic><topic>Ischemic Stroke - drug therapy</topic><topic>Meta-Analysis as Topic</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Study Protocol Systematic Review</topic><topic>Systematic Reviews as Topic</topic><topic>Tenecteplase - administration & dosage</topic><topic>Tenecteplase - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Guanfeng</creatorcontrib><creatorcontrib>Bai, Chunfeng</creatorcontrib><creatorcontrib>Zhu, Zhou</creatorcontrib><creatorcontrib>Li, Junheng</creatorcontrib><creatorcontrib>Shao, Sen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Guanfeng</au><au>Bai, Chunfeng</au><au>Zhu, Zhou</au><au>Li, Junheng</au><au>Shao, Sen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and safety of different doses of tenecteplase in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2021-01-22</date><risdate>2021</risdate><volume>100</volume><issue>3</issue><spage>e23805</spage><epage>e23805</epage><pages>e23805-e23805</pages><issn>0025-7974</issn><issn>1536-5964</issn><eissn>1536-5964</eissn><abstract>Tenecteplase is a modified recombinant tissue-plasminogen activator, which is effective and safe in the treatment of acute ischemic stroke. However, the therapeutic dose of tenecteplase has been controversial. The purpose of this study is to systematically investigate the efficacy and safety of different doses of tenecteplase thrombolytic therapy for acute ischemic stroke.
Computer retrieval of English databases (PubMed, EMBASE, Web of Science, the Cochrane Library) and Chinese databases (CNKI, Wanfang, Viper, and Chinese Biomedical Database) is conducted for a randomized controlled clinical study on thrombolytic treatment of acute ischemic stroke with different doses of tenecteplase from the establishment of the database to October 2020. Two researchers independently conduct data extraction and literature quality evaluation on the quality of the included studies, and meta-analysis is conducted on the included literatures using RevMan5.3 software.
In this study, National Institute of Health Stroke Scale (NIHSS) score, Modified Rankin Scale (mRS) score scale, symptomatic intracranial hemorrhage (SICH) incidence, All-cause mortality, and so on are used to evaluate the efficacy and safety of tenecteplase thrombolytic therapy in acute ischemic stroke with different doses.
This study will provide reliable evidence-based evidence for the clinical application of different doses of tenecteplase in thrombolytic therapy for acute ischemic stroke.
DOI 10.17605/OSF.IO/2MPCW.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>33545944</pmid><doi>10.1097/MD.0000000000023805</doi><orcidid>https://orcid.org/0000-0002-3578-5704</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2021-01, Vol.100 (3), p.e23805-e23805 |
| issn | 0025-7974 1536-5964 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7837936 |
| source | Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - therapeutic use Humans Ischemic Stroke - drug therapy Meta-Analysis as Topic Randomized Controlled Trials as Topic Study Protocol Systematic Review Systematic Reviews as Topic Tenecteplase - administration & dosage Tenecteplase - therapeutic use |
| title | Effectiveness and safety of different doses of tenecteplase in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A06%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20safety%20of%20different%20doses%20of%20tenecteplase%20in%20the%20treatment%20of%20acute%20ischemic%20stroke:%20A%20protocol%20for%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Chen,%20Guanfeng&rft.date=2021-01-22&rft.volume=100&rft.issue=3&rft.spage=e23805&rft.epage=e23805&rft.pages=e23805-e23805&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000023805&rft_dat=%3Cproquest_pubme%3E2487156812%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2487156812&rft_id=info:pmid/33545944&rfr_iscdi=true |